Promising remissions in relapsed refractory classical Hodgkin lymphoma patients requiring multiple salvage regimens before transplantation in the brentuximab vedotin era
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia Research Reports"
DOI: 10.1016/j.lrr.2021.100276
Abstract: Relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients refractory to first line salvage have poor outcomes. Herein we report the outcome of R/R cHL patients requiring ≥two vs. one line in the era of chemo-immunotherapy. Among… read more here.
Keywords: relapsed refractory; patients requiring; hodgkin lymphoma; classical hodgkin ... See more keywords
Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-09-772681
Abstract: Addition of brentuximab vedotin, a CD30-targeted antibody-drug conjugate, and the programmed death 1 (PD-1) inhibitors nivolumab and pembrolizumab to the armamentarium for transplant-ineligible relapsed/refractory classical Hodgkin lymphoma has resulted in improved outcomes, including the potential… read more here.
Keywords: transplant ineligible; relapsed refractory; hodgkin lymphoma; classical hodgkin ... See more keywords